Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS's immunotherapy ipilimumab shows survival benefit in Phase III advanced melanoma trial

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb's novel anti-CTLA-4 immunotherapy ipilimumab has improved overall survival by close to four months in a Phase III trial in previously treated melanoma, compared with an experimental therapeutic cancer vaccine (gp100) that has been extensively tested in the disease, data presented at the ASCO meeting in Chicago show.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts